期刊
CELL
卷 169, 期 4, 页码 736-749出版社
CELL PRESS
DOI: 10.1016/j.cell.2017.04.016
关键词
-
资金
- SNSF
- SystemsX Transfer Project Friends and Foes
- SystemsX MetastasiX grant
- European Research Council (ERC) under the European Union/ERC [336921]
- Roche
- EMBO - European Commission [ALTF 970-2014, GA-2013-609409]
- RACP CSL Fellowship
- CIHR/KCC SHOPP Fellowship
- NHMRC [628939]
- NIH [DP1-HD084071, R01CA164729]
- SNSF [31003A_152851]
- Zurich Cancer League grant
- Stiftung fur Forschung in der Onkologie grant
- University Research Priority Project Translational Cancer Research grant
- MSK Cancer Center [P30 CA008748]
- F. Hoffmann-La Roche AG
- Swiss National Science Foundation (SNF) [31003A_152851] Funding Source: Swiss National Science Foundation (SNF)
- European Research Council (ERC) [336921] Funding Source: European Research Council (ERC)
Immune cells in the tumor microenvironment modulate cancer progression and are attractive therapeutic targets. Macrophages and T cells are key components of the microenvironment, yet their phenotypes and relationships in this ecosystem and to clinical outcomes are ill defined. We used mass cytometry with extensive antibody panels to perform in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and five healthy controls. In 3.5 million measured cells, we identified 17 tumor-associated macrophage phenotypes, 22 T cell phenotypes, and a distinct immune composition correlated with progression-free survival, thereby presenting an in-depth human atlas of the immune tumor microenvironment in this disease. This study revealed potential biomarkers and targets for immunotherapy development and validated tools that can be used for immune profiling of other tumor types.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据